ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EKF Ekf Diagnostics Holdings Plc

26.95
0.00 (0.00%)
Last Updated: 08:00:11
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 26.95 26.80 28.70 - 4 08:00:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 66.64M -10.1M -0.0222 -12.14 122.6M
Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 26.95p. Over the last year, Ekf Diagnostics shares have traded in a share price range of 22.50p to 37.50p.

Ekf Diagnostics currently has 454,930,564 shares in issue. The market capitalisation of Ekf Diagnostics is £122.60 million. Ekf Diagnostics has a price to earnings ratio (PE ratio) of -12.14.

Ekf Diagnostics Share Discussion Threads

Showing 4201 to 4220 of 4800 messages
Chat Pages: Latest  180  179  178  177  176  175  174  173  172  171  170  169  Older
DateSubjectAuthorDiscuss
08/4/2022
11:41
Wise words indeed - can't agree more.
tongosti
08/4/2022
07:53
Re buybacks , IMO they have bought way too soon

The 9M is about to dry up today with 200k buybacks left

No sensible investor would have weighed in with this falling knife situation

You wait till the chart forms a bottom

buywell3
08/4/2022
06:29
Spotted the rns.. whilst investors like to see companies buying businesses to increase their business and revenues.! In these markets it makes sense to buy back your own shares whilst the price is cheap and give the share price protection from unnecessary pain. Novacyt should have done it.
bobdown2
07/4/2022
17:32
True that but you are now talking about something different in that you are talking about the way you decide to "source" opportunities in the markets rather than tour your entry / exit positions (which are always aligned (long or short) if one is to turn a profit) Re commods - the entire complex. Check out SALL - a very comprehensive ETP giving you inverse exposure to the whole basket. Good luck.
tongosti
07/4/2022
17:21
I mean the market does not always price stocks correctly. It's driven by supply & demand, and irrational at times.

Which commodities?

cisk
07/4/2022
17:07
And yea been having a short for ages on ekf (otherwise why would I appear on this board). small position though - not out of want but out of circumstances. One can't shift a proper size on the short side with such a minnow like ekf (this doesn't hold true on the long side of one builds up a position over several days).
tongosti
07/4/2022
16:40
Not sure what you are trying to say but Mr Market is always right. FACT not fiction (one only makes money by being on the right side (long or short) of him - please let me know if you may have discovered another way , keen to learn). Don’t take my word for it. Take Paul Tudor Jones’ / Jim Simons’s / Stan Druckenmller’s (or Jesse Livermore’s if you care to go a bit back in history of market giants). Look them up.

No stock exposure at the moment. Gradually building a short commodities position whilst biding my time to go short rates (when stars align).

tongosti
07/4/2022
15:53
Tong, you are correct and I walked back my comment at the time. Investing isn't personal, we may differ in approaches and tone but that's what makes life interesting.

I do disagree with your view on Mr Market though. He's not the judge of all, not by a long stretch. And it implies the market always gets it right -all of the time - which never happens.

Anyway, did you short EKF down from the 80s? And where else are you casting your net?

As for Wan, I appreciate his wider posts on the subject matter, and understand his enthusiasm, but assess objectively.

cisk
07/4/2022
15:08
Tong, congratulations on your clairvoyance. I'm sure I stand with other posters on this board in appreciation.
cisk
06/4/2022
15:48
High volumes breaking down below 40. Am sure wan will find a fresh of reasons to be cheerful tomorrow whilst all previous paper profits evaporate
tongosti
06/4/2022
13:44
Hope you're feeling much better pal. Explanation in two sentences: 1. there were no disbelievers left meaning the business has been having to catch-up with sky high expectations of tree growing to the sky 2. C19 business related boost was priced in way before the vaccine news broke out.
tongosti
06/4/2022
12:52
Having been absent from the market for some time due to health reasons I was shocked to see the collapse in the share price here from 80pish on my return.Cant see any news that would justify such a fall.Can anyone offer an explanation? Many thanks.
nurdin
06/4/2022
06:52
I note Yourgene are set to layout their roadmap and growth plans -

06/04/2022 7:01am
RNS Non-Regulatory

Yourgene Health PLC

06 April 2022

Yourgene Health plc

("Yourgene" or the "Company")

Capital Markets Day

Manchester, UK - 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April 2022.

The event will provide investors with a compelling opportunity to hear more from other senior members of the management team about the roadmap and growth plans for certain products and services, both in North America and internationally, as well as perspectives on the dynamics within the molecular diagnostics market and the scope for growing the Company's genomic services business.

An opening and closing address will be given by CEO, Lyn Rees who will provide an overview of the Company and where it is currently positioned. The event will also feature presentations by:

-- Dr Rachel Shelmerdine, Product Management
-- Scott Sargent, Vice President, Sales Americas
-- Bhavika Patel, Technical Director, Yourgene Genomic Services
-- Jonathan Seaton, Non-Executive Director, Yourgene Health plc
The event will be repeated in the City of London at 4pm for non-institutional investors and will be followed by light refreshments and an opportunity to talk to the senior management further.

wan
05/4/2022
12:29
Wan - if you have anything to say re demand supply for shares (the ultimate variable that matters) let us know pal. All ears.
tongosti
05/4/2022
11:53
just repaying the compliment dear chap wrongun
drew lonmenob
05/4/2022
11:46
Been wrong indeed Bobby doughnut from 80p down on here. Enjoying stalking me on these boards?
tongosti
05/4/2022
11:38
On the three day timeframe you have increasing volumes on the way down. In other words, the selling pressure far outweighs the other side of the trade. Hence the balance of odds favours the short side, as of now.
tongosti
05/4/2022
11:26
You got it wrong. Supply and demand for shares is what I was talking about. As in any other asset prices, interaction of demand and supply dictates what one gets for labour / houses / commodities / whatever. In the stock market it is SHARES. If you understood what drives imbalances in such an equation you would see what I see. Very funny supply and demand are crucial in economics but somehow folks have convinced themselves understanding it properly in finance is redundant?! Go figure what passes for common sense these days.
tongosti
05/4/2022
09:48
Staying with supply and demand as ultimately making or losing hard cash.

On the one hand EKF expects COVID-19 testing to continue, but for COVID-related revenues to materially reduce in 2022. Clearly COVID-19 had a very negative impact on other areas of the healthcare market in which EKF operate.

So, all things being equal, other healthcare markets will continue to significantly improve (and grow) as demonstrated by EKF Results detailing the performance of the core businesses segments.

In other words, there is a two way street in operation, albeit for the time being there is a speed restriction on our side of the street as EKF execute on the Growth Strategy and retransition to growth, which includes addressing opportunities in new markets and the distribution of new products, with EKF ultimately increasing their exposure to various growth areas of the healthcare and life science markets.

Put another way, EKF itself is not remotely stagnating, which is presumably why EKF's broker, Singer Capital Markets, viewed any share price weakness as a strong buying opportunity.

wan
05/4/2022
08:26
While Wan is getting ready to uncork the bubbly (for a change), the market is on the verge of a breakdown. If we touch 40, then 33 will be reached in the blink of an eye, in all likelihood. It's a very funny business where folks choose to ignore the number 1 fundamental - the interaction of demand and supply which ultimately makes or loses one cold hard cash!
tongosti
Chat Pages: Latest  180  179  178  177  176  175  174  173  172  171  170  169  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com